ABCB1 and ischemic stroke: Contrary to expectations based on the pharmacological profile of LEV as a P-glycoprotein inducer, our findings indicated that LEV does not significantly alter DOAC exposure or affect the incidence of ischemic stroke, STE, or major bleeding events.